Patterns of Radiological Recurrence Following Post-prostatectomy Salvage Radiotherapy
This study aimed to identify radiological patterns of failure in patients with early biochemical recurrence of prostate cancer treated by post-prostatectomy prostatic fossa radiotherapy. Secondary objectives included an exploratory analysis of prognostic factors, biochemical and radiological progression-free survival (bPFS and rPFS) and overall survival (OS). (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: E. Montague, S. Rodda, F. Slevin Source Type: research
Chemoradiotherapy for Muscle-invasive Bladder Cancer; 5-year Survival Outcomes, the Edinburgh Cancer Centre Experience
Purpose: Muscle-invasive bladder cancer (MIBC) constitutes about 30% of newly diagnosed bladder cancers. Only approximately 45% of patients survive for 5 years regardless of the type of treatment they receive [1]. Radical cystectomy has previously been considered standard therapy for MIBC. More recently, concurrent chemoradiotherapy (CRT) has emerged as an alternative treatment option [2]. A retrospective audit was carried out to review recurrence and survival rates amongst patients with MIBC treated with CRT at the Edinburgh Cancer Centre. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: J. Parry, E. Doyle, O. Curran, A. Law, D. McLaren, J. Malik Source Type: research
Relapse Rate in Node-positive Prostate Cancer Patients Treated with Radical Radiotherapy
Purpose: A recent multicentre retrospective analysis showed that prostate radiotherapy in clinically node-positive prostate cancer showed improved disease control and overall survival [1]. We aimed to assess the relapse rate and associated variables in clinically node-positive patients treated with radical radiotherapy at Barts Cancer Centre. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: H.Z. Poe Poe, Y. Milner, K. Tipples, P. Wells Source Type: research
The Beatson Experience of Hydrogel Vue Rectal Spacers in Patients at High Risk of Rectal Toxicity from Prostate Radiotherapy
We describe our experience of Hydrogel Vue biodegradable spacers inserted in patients considered to be at higher risk of radiotherapy-induced rectal toxicity. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: J. Saunders, A. Alhasso, I. Ahmad Source Type: research
Assessing the Value of CT in the Staging and Management of High-risk Prostate Cancer Patients
Purpose: Pelvic magnetic resonance (MR) imaging and isotope bone scans (BS) to exclude locoregional or distant metastatic spread are recommended in men with high-risk prostate cancer (PCa) by national and international guidelines [1 –3]. The added benefit of computerised tomography (CT) staging is less clear. We aimed to assess the addition of CT to staging and management of PCa. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: M. Swinton, C. Carey, N. Cripps, F. Elsawy, S. Lodhi, J. Wylie Source Type: research
Developing an MR Signature of Prostate Hypoxia for the MR-Linac
Purpose: Intra-tumoral hypoxia in prostate cancer (PCa) is associated with worse prognosis after radical treatment [1,2]. MRI detection of hypoxia could identify men who benefit from hypoxia-modification or treatment intensification. We aimed to validate hypoxia-detection sequences in PCa acquired on the MR-Linac. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: M. Swinton, D. McHugh, M. Dubec, D. Buckley, R. Bristow, A. Choudhury Source Type: research
Current Practice of Apalutamide in Patients with Metastatic Hormone-sensitive Prostate Cancer
Purpose: Apalutamide is an oral antiandrogen therapy currently licensed in the UK for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). This is based on randomised control trial evidence showing favourable overall survival with apalutamide plus ADT compared with ADT and placebo (HR for death 0.67, P = 0.005) [1]. A multicentre observational study in the UK, ADAPT-P, will look at real-world and patient-reported outcomes, as well as the healthcare professional perspective on apalutamide use. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: C. Thompson, J. Murray, G. Bucinskaite, K. Jones, L. Satchwell, Z. Rajan Source Type: research
Use of WB-MRI to Evaluate the Distribution of Tumour Burden after Initial Systemic Therapy in High Volume Metastatic Hormone-sensitive Prostate Cancer Patients
Purpose: Metastatic hormone-sensitive prostate cancer (mHSPC) can be classified as high or low volume on conventional imaging (CT and bone scan) [1]. However, the optimal imaging modality for evaluating response to treatment is yet to be determined. Whole body diffusion-weighted MRI (WB-DWI MRI) is more sensitive than conventional imaging at detecting bone metastases and assessing response to therapy [2]. Standard of care treatment for mHSPC is androgen deprivation (ADT) plus systemic therapy (androgen receptor targeted agent [ARTA] ± docetaxel chemotherapy). (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: C. Thompson, N. Tunarui, A. Tree, A. Reid, C. Parker, J. Murray Source Type: research
A Retrospective Evaluation of Clinical Outcomes of Patients Undergoing Cystectomy for Bladder Cancer at a Specialist Centre; Real-world Data from University College London Hospital
In this study, we looked at the outcomes of patients receiving neoadjuvant chemotherapy, with particular focus on patients with variant histology. Bladder cancer encompasses heterogenous pathological entities and patients with rare histological subtypes are typically excluded from trials, so outcome data are limited. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: M. Veli, A. Freeman, C. Alifrangis, A. Sridhar, M. Linch, U. McGovern Source Type: research
Salvage Radiotherapy in Localised Prostate Cancer Patients over a 4-year Follow-up Period: Single Centre Analysis
We describe real-world data of patients referred for SR post-RARP with a focus on change in practice over a 4-year follow-up period. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: L. Walshaw, K.N. Patel, B. Gammer, A. Robinshon Source Type: research
RCR Meetings
(Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Source Type: research
OncoFlash – Research updates in a Flash! January 24 edition
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Chang JY, Lin SH, Dong W, Liao Z et al.; Lancet, 2023 [1] (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: D. Shor, R. Simoes Source Type: research
Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis
The aim of this network meta-analysis was to elucidate the efficacy and safety of various immune checkpoint inhibitors (ICIs) used in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC). (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: Ting Mei, Qinghua Zhou, Youling Gong Tags: Original Article Source Type: research
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials
The combination of 5-fluorouracil/leucovorin (5-FU/LV) plus oxaliplatin (FOLFOX) is widely acknowledged as the standard regimen for second-line treatment in patients with advanced biliary tract cancer. Nanoliposomal irinotecan (nal-IRI) has demonstrated its activity in patients with advanced pancreatic cancer. Recent studies have investigated the activity of nal-IRI in combination with 5-FU/LV for biliary tract cancer. However, the results have been contradictory. We conducted a meta-analysis to assess survival outcomes and response rates in randomised trials investigating the activity of nal-IRI in previously treated bili...
Source: Clinical Oncology - December 14, 2023 Category: Radiology Authors: V. Merz, C. Messina, C. Zecchetto, A. Quinzii, M. Frisinghelli, C. Trentin, M. Salati, O. Caffo, D. Melisi Tags: Original Article Source Type: research
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials
The combination of 5-fluorouracil/leucovorin (5-FU/LV) plus oxaliplatin (FOLFOX) is widely acknowledged as the standard regimen for second-line treatment in patients with advanced biliary tract cancer. Nanoliposomal irinotecan (nal-IRI) has demonstrated its activity in patients with advanced pancreatic cancer. Recent studies have investigated the activity of nal-IRI in combination with 5-FU/LV for biliary tract cancer. However, the results have been contradictory. We conducted a meta-analysis to assess survival outcomes and response rates in randomised trials investigating the activity of nal-IRI in previously treated bili...
Source: Clinical Oncology - December 14, 2023 Category: Radiology Authors: V. Merz, C. Messina, C. Zecchetto, A. Quinzii, M. Frisinghelli, C. Trentin, M. Salati, O. Caffo, D. Melisi Tags: Original Article Source Type: research
